Scholarlink

<p>Phenotypic plasticity and drug tolerance are now recognized as major causes of tumor aggressiveness and therapy resistance. Melanoma represents a paradigmatic example of how solid tumors exploit non-genetic adaptive programs, including the transition between proliferative and dormant states and the emergence of drug-tolerant persister cells, that sustain intratumoral heterogeneity and survive targeted and immune-based therapies. Increasing evidence shows that miRNAs are critical elements controlling these processes both directly, via shaping gene expression programs that enable cell plasticity, and indirectly, through vesicle-mediated communication that spreads resistant traits and remodels the tumor microenvironment. The combined impact on cell-intrinsic and cell-extrinsic pathways position miRNAs as promising biomarkers and therapeutic targets across malignancies. Even though early therapeutic efforts faced challenges in delivery and stability, recent advances in chemically modified antisense oligonucleotides, particularly locked nucleic acids (LNAs), have renewed interest in targeting oncogenic miRNAs in metastatic disease. This review combines current knowledge on phenotypic plasticity, drug-tolerant states and microenvironmental remodeling, with miRNA regulation, highlighting how insights gained from melanoma can shape the development of clinically relevant LNA-based therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

miRNA-driven cancer cell plasticity, tolerance and therapy resistance: lessons from melanoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Arianna Ortolano,
  • Rachele Frigerio,
  • Gennaro Ciliberto,
  • Luigi Fattore,
  • Rita Mancini

摘要

Phenotypic plasticity and drug tolerance are now recognized as major causes of tumor aggressiveness and therapy resistance. Melanoma represents a paradigmatic example of how solid tumors exploit non-genetic adaptive programs, including the transition between proliferative and dormant states and the emergence of drug-tolerant persister cells, that sustain intratumoral heterogeneity and survive targeted and immune-based therapies. Increasing evidence shows that miRNAs are critical elements controlling these processes both directly, via shaping gene expression programs that enable cell plasticity, and indirectly, through vesicle-mediated communication that spreads resistant traits and remodels the tumor microenvironment. The combined impact on cell-intrinsic and cell-extrinsic pathways position miRNAs as promising biomarkers and therapeutic targets across malignancies. Even though early therapeutic efforts faced challenges in delivery and stability, recent advances in chemically modified antisense oligonucleotides, particularly locked nucleic acids (LNAs), have renewed interest in targeting oncogenic miRNAs in metastatic disease. This review combines current knowledge on phenotypic plasticity, drug-tolerant states and microenvironmental remodeling, with miRNA regulation, highlighting how insights gained from melanoma can shape the development of clinically relevant LNA-based therapeutics.